Cosunter(SZ:300436) Xin Lang Cai Jing·2025-11-07 05:48Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.09% to 102.88 CNY per share, with a trading volume of 722 million CNY and a turnover rate of 5.01%, resulting in a total market capitalization of 16.385 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 3.909 million CNY. The fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY, and has achieved a year-to-date return of 21.69% [2] - The fund's one-year return is 13.44%, ranking 5002 out of 8053 in its category, while since its inception, it has achieved a return of 110.03% [2]